Clarus Therapeutics Holdings, Inc., recently announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover its oral testosterone replacement product, Jatenzo (testosterone undecanoate).
Related posts
-
Suburban skaters mourn D.C. plane crash victims they’d just seen at Kansas competition
Some of the victims on the American Eagle flight that crashed into the Potomac River after... -
Suburban skaters mourn D.C. plane crash victims they’d just seen at Kansas competition
Some of the victims on the American Eagle flight that crashed into the Potomac River after... -
The MSL’s tradition should not be taken lightly
While the realignment plans for the Mid-Suburban League carry a noble goal, the loss of tradition...